中晚期宫颈癌的治疗方案比较研究

Curative effect of therapy methods on medium-and advanced stage cervical cancer

目的比较治疗中晚期宫颈癌同步放化疗的化疗方案。方法 96例中晚期宫颈癌患者同步放化疗随机分成顺铂同步放化疗(30例)、紫杉醇同步放化疗(32例)和贝伐单抗同步放化疗组(28例),观察和比较3组的治疗效果和副反应。结果 3组治疗方案的近期有效率分别为96.7%、100%和100%,无显著性差异(P>0.05);顺铂同步放化疗与紫杉醇同步放化疗组相比,5年生存率无显著性差异(P>0.05);顺铂同步放化疗和贝伐单抗同步放化疗相比,5年生存率有显著性差异(P<0.05);紫杉醇同步放化疗和贝伐单抗同步放化疗组相比,5年生存率有显著性差异(P<0.05)。顺铂同步放化疗、紫杉醇同步放化疗有较明显的消化道反应和骨髓抑制,而且肾功损害明显,贝伐单抗同步放化疗组相比有显著性差异(P<0.05)。结论贝伐单抗同步放化疗方案与其它两组方案相比,能明显提高患者的生存率,同时副反应相对较轻。

Objective： To compare better chemotherapy method of concurrent chemotherapy and radiotherapy onmedium- and advanced stage cervical cancer. Methods： The 90 cases with medium- and advanced stage cervical cancer treated by concurrent chetherapy and radiotherapy were randomized into three groups： Cisplatin group（ 30cases）,docetaxel group（ 32cases）,and bevacizumab group（ 28 cases）. The curative effectiveand side effect were observed and compared. Results： Effective rate was96. 7% 、100% and 100% for cisplatin group,docetaxel groupand bevacizumab group after radiotherapy,with no significant differenceamong them（ P〉0. 05）. The rate of 5- year survival was 20% and 18% for Cisplatin group,docetaxel group,lower than bevacizumab group 35%（ P〈0. 05）,but there was no significant differencebetween the cisplatin and docetaxel group（ P〉0. 05）. There was obviously side- effect of digestivetract and bone marrow inhibition and kidney damage in cisplatin and docetaxel group,when compared to bevacizumab group 35%（ P〈0. 05）. Conclusion： Bevacizumab can significantly improve the patients＇ survival,with less side- effect in medium- and advanced stage cervical cancer.